Skip to content
DataLookout
Menu

EMERALDNCT07932145

Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change From Baseline in Mean Daytime Ambulatory Systolic Blood Pressure at Week 12
Timeframe: Baseline and Week 12

Secondary (12)

Change From Baseline in Office Systolic Blood Pressure
Change From Baseline in Office Diastolic Blood Pressure
Percentage of Participants Achieving Office Blood Pressure Control
Percentage of Participants Achieving an Office Blood Pressure Response
Number of Antihypertensive Treatment Adjustments
Show 7 moreShow less
Time to First Documented Office Blood Pressure Control
Mean 24-Hour Ambulatory Systolic Blood Pressure
Mean 24-Hour Ambulatory Diastolic Blood Pressure
Mean Nighttime Ambulatory Systolic Blood Pressure
Mean Nighttime Ambulatory Diastolic Blood Pressure
Mean Daytime Ambulatory Diastolic Blood Pressure
Antihypertensive Medication Burden at Achievement of Target Office Blood Pressure

Arms and interventions

Early Eplerenone-Based TreatmentExperimental

Participants will receive stepped antihypertensive treatment starting with eplerenone 50 mg orally once daily. Treatment will be intensified as needed by sequentially adding amlodipine 5 mg once daily, increasing eplerenone to 50 mg twice daily, increasing amlodipine to 5 mg twice daily, adding hydrochlorothiazide 12.5 mg once daily, adding doxazosin 4 mg once daily, and increasing hydrochlorothiazide to 25 mg once daily. Participants taking two antihypertensive drugs before washout will generally start with eplerenone plus amlodipine. Treatment adjustments will depend on blood pressure, tolerability, and safety assessments, with a target seated office blood pressure below 140/90 mmHg. Treatment will continue for 24 weeks.

Standard TreatmentActive comparator

Participants will receive stepped antihypertensive treatment starting with telmisartan 40 mg orally once daily. Treatment will be intensified as needed by sequentially adding amlodipine 5 mg once daily, increasing telmisartan to 80 mg once daily, increasing amlodipine to 5 mg twice daily, adding hydrochlorothiazide 12.5 mg once daily, adding doxazosin 4 mg once daily, and increasing hydrochlorothiazide to 25 mg once daily. Participants taking two antihypertensive drugs before washout will generally start with telmisartan plus amlodipine. Treatment adjustments will depend on blood pressure, tolerability, and safety assessments, with a target seated office blood pressure below 140/90 mmHg. Treatment will continue for 24 weeks.

Drugs: Eplerenone, Telmisartan

Sites

1 site in 1 country

  • Fuwai HospitalBeijing, Beijing Municipality, China